Published in Cancer Genomics Proteomics on March 25, 2010
Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis (2011) 1.00
TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer (2010) 0.97
Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation. Asian J Androl (2012) 0.95
Deregulation of an imprinted gene network in prostate cancer. Epigenetics (2014) 0.93
Protectors or Traitors: The Roles of PON2 and PON3 in Atherosclerosis and Cancer. J Lipids (2012) 0.88
Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLoS One (2013) 0.86
TGF-β mediated DNA methylation in prostate cancer. Transl Androl Urol (2012) 0.85
Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis (2011) 0.84
Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma. Cancer Sci (2014) 0.83
P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway. Cancer Res (2014) 0.81
Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses. BMC Cancer (2013) 0.80
Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma. Clin Epigenetics (2014) 0.80
Paraoxonase 2 serves a proapopotic function in mouse and human cells in response to the Pseudomonas aeruginosa quorum-sensing molecule N-(3-Oxododecanoyl)-homoserine lactone. J Biol Chem (2015) 0.78
Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers. Br J Cancer (2015) 0.77
Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray. BMC Urol (2013) 0.76
Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis. J Cancer Res Clin Oncol (2015) 0.76
Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget (2017) 0.75
Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells. Exp Ther Med (2017) 0.75
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res (2010) 2.95
Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res (2002) 2.34
Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol (2005) 1.94
Chromosomal instability in bladder cancer. Arch Toxicol (2008) 1.59
Downregulation of several fibulin genes in prostate cancer. Prostate (2007) 1.46
Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis (2003) 1.43
The rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development. J Biol Chem (2005) 1.33
Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol (2007) 1.30
DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol (2013) 1.30
Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol (2002) 1.29
Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer (2002) 1.28
Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res (2003) 1.21
CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia (2009) 1.21
Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol (2010) 1.19
Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics (2005) 1.18
S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One (2011) 1.17
Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene (2004) 1.15
Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. Mol Cancer (2005) 1.14
Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol (2006) 1.13
Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma. Int J Cancer (2003) 1.10
Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature. Hum Pathol (2008) 1.09
The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells. J Cell Mol Med (2010) 1.08
Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res (2014) 1.08
Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther (2007) 1.05
Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol (2007) 1.03
Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biol (2010) 1.03
Desmoplastic fibroma of the mandible--review of the literature and presentation of a rare case. Head Face Med (2009) 1.01
Selective changes of retroelement expression in human prostate cancer. Carcinogenesis (2011) 1.00
Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res (2009) 1.00
DNA methylation changes in prostate cancer. Methods Mol Biol (2012) 1.00
DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther (2006) 0.99
Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer (2007) 0.98
Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer (2005) 0.98
Hedgehog signaling regulates bladder cancer growth and tumorigenicity. Cancer Res (2012) 0.97
Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol (2009) 0.97
Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation. Asian J Androl (2012) 0.95
Characteristics of testicular dysgenesis syndrome and decreased expression of SRY and SOX9 in Frasier syndrome. Mol Reprod Dev (2008) 0.93
Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. Clin Chem (2005) 0.93
Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer (2003) 0.92
Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol (2012) 0.92
Methylenetetrahydrofolate reductase C677T polymorphism and predisposition towards esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. J Cancer Res Clin Oncol (2004) 0.92
Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. Genes Chromosomes Cancer (2005) 0.91
Distinctive differences in DNA double-strand break repair between normal urothelial and urothelial carcinoma cells. Mutat Res (2007) 0.91
Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer. Int J Cancer (2008) 0.91
Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics (2008) 0.90
Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer. Mol Cancer Res (2006) 0.89
Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines. J Cell Physiol (2005) 0.89
In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. Exp Mol Pathol (2006) 0.88
Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer (2010) 0.88
Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. Auris Nasus Larynx (2009) 0.87
p27KIP1-expression in human renal cell cancers: implications for clinical outcome. Anticancer Res (2003) 0.87
A single nucleotide polymorphism determines protein isoform production of the human c-FLIP protein. Blood (2009) 0.87
Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Urol Oncol (2011) 0.87
Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells. Genes Chromosomes Cancer (2003) 0.86
HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma. Front Oncol (2013) 0.86
EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. J Transl Med (2011) 0.85
A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol (2007) 0.85
Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Urology (2004) 0.85
ID4 is frequently downregulated and partially hypermethylated in prostate cancer. World J Urol (2011) 0.84
Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer. Prostate (2002) 0.84
Imbalances of chromosome arm 1p in pediatric and adult germ cell tumors are caused by true allelic loss: a combined comparative genomic hybridization and microsatellite analysis. Genes Chromosomes Cancer (2006) 0.83
The SNP rs6441224 influences transcriptional activity and prognostically relevant hypermethylation of RARRES1 in prostate cancer. Int J Cancer (2012) 0.82
Hypomethylation of the XIST gene promoter in prostate cancer. Oncol Res (2005) 0.82
Methylenetetrahydrofolate reductase C677T polymorphism and risk of adenocarcinoma of the upper gastrointestinal tract. Scand J Gastroenterol (2005) 0.82
Activity of E2F-dependent promoters in bladder carcinoma cells and their use for tumour-specific targeting of p53-induced apoptosis. Int J Oncol (2002) 0.82
Do DNA-methylation changes also occur in blood? Lancet Oncol (2008) 0.82
Squamous cell carcinoma arising from a localized vulval lesion of Hailey-Hailey disease after tacrolimus therapy. Am J Obstet Gynecol (2010) 0.81
Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines. Cell Oncol (Dordr) (2012) 0.81
Sporadic solitary aldosterone- and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism. Hypertens Res (2010) 0.81
Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage. Eur Urol (2005) 0.81
DNA methylation in placentas of interspecies mouse hybrids. Genetics (2003) 0.81
Eagles report: Developing cancer biomarkers from genome-wide DNA methylation analyses. World J Clin Oncol (2011) 0.80
Uropathogenic bacteria leave a mark. Lab Invest (2011) 0.79
Daxx-beta and Daxx-gamma, two novel splice variants of the transcriptional co-repressor Daxx. J Biol Chem (2011) 0.79
Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation. Tumour Biol (2015) 0.79
Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation. Eur J Cancer (2006) 0.79
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. J Exp Clin Cancer Res (2014) 0.78
[Radiotherapy of soft tissue sarcoma--part of a multidisciplinary strategy]. Wien Klin Wochenschr (2008) 0.78
p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer. Urol Int (2002) 0.77
DNA Methylation and the HOXC6 Paradox in Prostate Cancer. Cancers (Basel) (2011) 0.77
Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer. Oncol Res Treat (2014) 0.77
Recent insights into regulation of transcription by RNA polymerase III and the cellular functions of its transcripts. Biol Chem (2011) 0.76
Suppression of clonogenicity by mammalian Dnmt1 mediated by the PCNA-binding domain. Biochem Cell Biol (2004) 0.75
Leser-Trélat sign presenting in a patient with ovarian cancer: a case report. J Med Case Rep (2009) 0.75